Literature DB >> 11593283

Reversible posterior leucoencephalopathy syndrome associated with bone marrow transplantation.

H A Teive1, I V Brandi, C H Camargo, M A Bittencourt, C M Bonfim, M L Friedrich, C R de Medeiros, L C Werneck, R Pasquini.   

Abstract

Reversible posterior leucoencephalopathy syndrome (RPLS) has previously been described in patients who have renal insufficiency, eclampsia, hypertensive encephalopathy and patients receiving immunosuppressive therapy. The mechanism by which immunosuppressive agents can cause this syndrome is not clear, but it is probably related with cytotoxic effects of these agents on the vascular endothelium. We report eight patients who received cyclosporine A (CSA) after allogeneic bone marrow transplantation or as treatment for severe aplastic anemia (SSA) who developed posterior leucoencephalopathy. The most common signs and symptoms were seizures and headache. Neurological dysfunction occurred preceded by or concomitant with high blood pressure and some degree of acute renal failure in six patients. Computerized tomography studies showed low-density white matter lesions involving the posterior areas of cerebral hemispheres. Symptoms and neuroimaging abnormalities were reversible and improvement occurred in all patients when given lower doses of CSA or when the drug was withdrawn. RPLS may be considered an expression of CSA neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11593283     DOI: 10.1590/s0004-282x2001000500024

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  7 in total

1.  Tacrolimus-related encephalopathy following allogeneic stem cell transplantation in children.

Authors:  Takahisa Kanekiyo; Junichi Hara; Yoshiko Matsuda-Hashii; Hiroyuki Fujisaki; Sadao Tokimasa; Akihisa Sawada; Keiko Kubota; Kuriko Shimono; Katsumi Imai; Keiichi Ozono
Journal:  Int J Hematol       Date:  2005-04       Impact factor: 2.490

Review 2.  Spontaneous posterior fossa hemorrhage associated with low-molecular weight heparin in an adolescent recently diagnosed with posterior reversible encephalopathy syndrome: case report and review of the literature.

Authors:  Theofilos G Machinis; Kostas N Fountas; Vassilios G Dimopoulos; E Christopher Troup
Journal:  Childs Nerv Syst       Date:  2006-09-08       Impact factor: 1.475

3.  The posterior reversible encephalopathy syndrome.

Authors:  K Mandal Sanjay; P Chakraborty Partha
Journal:  Indian J Pediatr       Date:  2008-09-22       Impact factor: 1.967

4.  Reversible encephalopathy syndrome: report of 12 cases with follow-up.

Authors:  S Greco Crasto; L Rizzo; P Sardo; O Davini; R De Lucchi
Journal:  Neuroradiology       Date:  2004-10       Impact factor: 2.804

5.  Posterior reversible encephalopathy in a child with Langerhans cell histiocytosis following allogeneic PBSCT treatment with cyclosporine.

Authors:  Chi-Chieh Lai; Shyi-Jou Chen; Shao-Hung Lien; Chung-Ping Lo; Shin-Nang Cheng
Journal:  Eur J Pediatr       Date:  2007-07-26       Impact factor: 3.183

6.  Reversible posterior leukoencephalopathy associated with chronic graft-versus-host disease: A case report.

Authors:  Jinbei Yu; Lichao Sun; Weihong Lin
Journal:  Exp Ther Med       Date:  2016-04-08       Impact factor: 2.447

7.  Atypical reversible leucoencephalopathy syndrome after bevacizumab/folfox regimen for metastatic colon cancer.

Authors:  Narimane Salmi; Ibrahim Elghissassi; Khadija Bellahammou; Asmaa Lakhdissi; Hind Mrabti; Hassan Errihani
Journal:  Case Rep Oncol Med       Date:  2014-10-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.